摘要
目的 探讨依达拉奉对重度颅脑外伤（SHI）患者预后及血浆8-表氧前列腺素F2α（8-iso-PGF2α）水平的影响.方法 68例SHI患者在知情同意情况下,按入院序号随机均分为治疗组和对照组各34例,两组均给予常规治疗,治疗组在此基础上加用依达拉奉注射液治疗,治疗14 d.观察比较两组血浆8-iso-PGF2α水平、格拉斯哥昏迷评分（GCS）及预后分级评分（GOS）等情况.结果 治疗组治疗第7、14、30天时,治疗组血浆8-iso-PGFF2α水平分别为（18.84±3.96）、（14.21±3.67）、（12.98±4.03）ng/L,显著低于对照组的（25.53±4.01）、（21.08±3.40）、（16.64±3.78）ng/L（t=7.56、6.98、8.54,均P＜0.05）.治疗组治疗前、治疗14 d后GCS评分分别为（4.49±1,21）分、（12.34±2.47）分,对照组分别为（4.36 ±1.13）分、（10.45±1.65）分,两组治疗14 d后GCS评分与其治疗前差异均有统计学意义（t=6.43、7.21,均P＜0.05）,两组治疗14 d后GCS评分差异有统计学意义（t=7.44,P＜0.05）;治疗组3个月GOS评分为（4.76±1.54）分,明显高于对照组的（3.51±1.33）分（t=5.32,P＜0.05）.治疗3个月后,治疗组良好16例、中残6例、重残4例、植物生存3例、死亡5例,对照组分别为9例、7例、5例、2例、11例,两组临床疗效差异有统计学意义（μ=11.21,P＜0.05）.结论 应用依达拉奉可显著降低颅脑外伤患者血浆8-iso-PGF2α水平,改善患者预后.
Objective To explore the effect of edaravone on serum level of 8-iso-PGF2α and prognosis in patients with severe head injury（SHI）.Methods 68 patients with SHI were randomly divided into two groups,which were both given conventional treatment,while the treatment group was also given extra injection of edaravone for 14d.8-iso-PGF2α,GCS score and GOS were observed and compared between the two groups respectively.Results The decrease of serum level of 8-iso-PGF2α in treatment group was significantly higher than that of the control group,the GCS score and good outcomes after 3 months was significantly higher than that of the control group after the treatment（P＜0.05）.Conclusion Edaravone could reduce the serum level of 8-iso-PGF2α in SHI patients and improve the prognosis.which was woah clinical application.
出处
《中国基层医药》
CAS
2011年第11期1468-1469,共2页
Chinese Journal of Primary Medicine and Pharmacy
